EVT DE0005664809

Report

Real-time Estimate Tradegate - 09/20 03:44:41 pm
43.5	EUR		-1.52%

09/15	EVOTEC : publishes DDup 11 – AI-driven antibody discovery at Evotec	PU
09/06	EVOTEC PARTNER BAYER : Phase IIb trial shows eliapixant significantly decreases cough frequency in patients with refractory chronic cough	PU
09/02	KAZIA THERAPEUTICS : Evt801 phase i study receives full regulatory approval	AQ

Summary

Quotes 5-day view Delayed Quote.

Delayed Xetra

09/14/2021	09/15/2021	09/16/2021	09/17/2021	09/20/2021	Date
44.97(c)	45.35(c)	45.06(c)	44.17(c)	43.73	Last
437 900	484 060	496 088	1 320 376	607 808	Volume
+3.62%	+0.85%	-0.64%	-1.98%	-1.00%	Change

More quotes

Estimated financial data (e)

Sales 2021	564 M 660 M 660 M
Net income 2021	74,0 M 86,7 M 86,7 M
Net Debt 2021	61,0 M 71,5 M 71,5 M
P/E ratio 2021	97,1x
Yield 2021	-

Sales 2022	647 M 758 M 758 M
Net income 2022	42,6 M 49,9 M 49,9 M
Net Debt 2022	93,5 M 110 M 110 M
P/E ratio 2022	166x
Yield 2022	-

Capitalization	7 281 M 8 547 M 8 529 M
EV / Sales 2021	13,0x
EV / Sales 2022	11,4x
Nbr of Employees	3 914
Free-Float	87,1%

More Financials

Company

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug...

Sector

Biotechnology & Medical Research

Calendar

09/20

Presentation

More about the company

Ratings of Evotec SE

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

All news about EVOTEC SE

09/15	EVOTEC : publishes DDup 11 – AI-driven antibody discovery at Evotec	PU
09/06	EVOTEC PARTNER BAYER : Phase IIb trial shows eliapixant significantly decreases ..	PU
09/02	KAZIA THERAPEUTICS : Evt801 phase i study receives full regulatory approval	AQ
09/02	EVOTEC : and Secarna Pharmaceuticals expand strategic partnership in the field o..	PU
09/02	PRESS RELEASE : Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals a..	DJ
09/02	Secarna Pharmaceuticals and Evotec Expand Strategic Partnership in the Field ..	CI
09/02	KAZIA THERAPEUTICS : Secures French Regulatory Approval for Phase 1 Trial of Can..	MT
09/02	EVOTEC : partner Kazia Therapeutics announces full regulatory approval for Phase..	PU
09/02	EVOTEC : announces Bristol Myers Squibb opt-in of EVT8683 as the first programme..	PU
09/02	EVOTEC : announces Bristol Myers Squibb opt-in of EVT8683 as the first programme..	EQ
09/02	PRESS RELEASE : Evotec announces Bristol Myers -2-	DJ
09/02	PRESS RELEASE : Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the f..	DJ
09/02	Evotec SE Announces Bristol Myers Squibb Opt-In of Evt8683 as the First Progr..	CI
09/01	Evotec SE english	DJ
08/31	DGAP-NVR : Evotec SE: Release according to Article 41 of the WpHG [the German Se..	DJ

More news

News in other languages on EVOTEC SE

09/15	EVOTEC : veröffentlicht DDup 11 - "AI-driven antibody discovery at Evotec"
09/13	Tagesvorschau international
09/13	TAGESVORSCHAU : Termine am 13. September 2021
09/10	TAGESVORSCHAU : Termine am 13. September 2021
09/03	EVOTEC IM FOKUS : Master of the Forschung im Börsenorbit

More news

Analyst Recommendations on EVOTEC SE

08/17	EVOTEC : Receives a Buy rating from Warburg Research	MD
08/16	EVOTEC : Deutsche Bank reiterates its Neutral rating	MD
08/12	EVOTEC : Deutsche Bank sticks Neutral	MD

More recommendations

Provided by Scoopnest.com

Analysis

GameStop rallies back as U.S. regulators eye wild trading